In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bayer HealthCare, Nektar to develop inhalable Cipro

Executive Summary

Bayer HealthCare AG and drug delivery company Nektar Therapeutics are collaborating to develop an inhalable formulation of Bayer's Cipro (ciprofloxacin) to treat chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register